Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Capital Expenditures (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Capital Expenditures for 6 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 137.67% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, up 80.24% year-over-year, with the annual reading at $1.4 million for FY2025, 80.24% up from the prior year.
  • Capital Expenditures for Q4 2025 was $1.4 million at Caribou Biosciences, up from -$1.5 million in the prior quarter.
  • The five-year high for Capital Expenditures was $11.1 million in Q4 2023, with the low at -$3.6 million in Q4 2024.
  • Average Capital Expenditures over 5 years is $853500.0, with a median of $498500.0 recorded in 2022.
  • Peak annual rise in Capital Expenditures hit 6762.96% in 2021, while the deepest fall reached 4392.86% in 2021.
  • Over 5 years, Capital Expenditures stood at $1.9 million in 2021, then plummeted by 74.85% to $466000.0 in 2022, then surged by 2272.75% to $11.1 million in 2023, then plummeted by 132.63% to -$3.6 million in 2024, then skyrocketed by 137.67% to $1.4 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $1.4 million, -$1.5 million, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.